ATHE Overview

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Wall Street analysts forecast ATHE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alterity Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased

Alterity Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased

Alterity Therapeutics Ltd (ATHE) has 9 emplpoyees as of May 24 2026.

Today ATHE has the market capitalization of 75.04M USD.